Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 98.00 | |
10 mg | In stock | $ 172.00 | |
25 mg | In stock | $ 363.00 | |
50 mg | In stock | $ 597.00 | |
100 mg | In stock | $ 955.00 | |
500 mg | In stock | $ 1,890.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 116.00 |
Description | Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor. |
Targets&IC50 | Akt3:8.1 nM, Akt2:14 nM, Akt1:2.7 nM |
In vitro | ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets[2]. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations[1]. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells[3]. |
Cell Research | Cells (MDA-MB-453: 1.5×106; NCI-H1650: 1×106; KU-19-19: 0.7×106) are plated into 6 well plates, left overnight, and then treated with full media containing different concentrations (0, 0.012, 0.037, 0.11, 0.33, and 1 μM) of AKT inhibitors (ARQ 092, ARQ 751, MK-2206, GDC-0068) for 2 hours. Cells are treated under designated conditions and lysates are extracted. Proteins are resolved from extracts using SDS-PAGE followed by immunoblotting. (Only for Reference) |
Synonyms | ARQ-092, AKT inhibitor 2 |
Molecular Weight | 432.52 |
Formula | C27H24N6 |
CAS No. | 1313881-70-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (115.6 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Miransertib 1313881-70-7 Cytoskeletal Signaling Microbiology/Virology PI3K/Akt/mTOR signaling Parasite Akt anti-proliferative PKB Akt1 Protein kinase B Inhibitor ARQ092 Akt3 AKT1-E17K Akt2 inhibit ARQ-092 p-PRAS40 ARQ 092 anti-tumor p-Akt AKT inhibitor 2 inhibitor